



## Evaline Cheng, MD

Clinical Assistant Professor, Medicine - Cardiovascular Medicine

### CLINICAL OFFICE (PRIMARY)

- **Cardiovascular Medicine**

300 Pasteur Dr

Falk Bldg CVRC MC 5406

Stanford, CA 94305

**Tel** (650) 723-6141      **Fax** (650) 723-8392

### Bio

---

#### BIO

Dr. Cheng is a non-invasive cardiologist specializing in cardio-oncology and a Clinical Assistant Professor in the Department of Medicine, Division of Cardiovascular Medicine, at Stanford University School of Medicine. She completed her fellowship in Cardiovascular Medicine at Stanford University.

In addition to providing care for general cardiovascular diseases, Dr. Cheng's clinical practice focuses on the cardiovascular care of cancer patients and survivors. She provides comprehensive, evidence-based cardiovascular care before, during, and after cancer treatment, with expertise in managing acute cardiotoxicities from cancer therapies and supporting the long-term heart health of cancer survivors.

Her research is dedicated to advancing care delivery for cardio-oncology patients. She is particularly interested in the risk assessment and management of cardiotoxicity related to cancer therapies. Her work has been supported by an NIH F32 award, which funded her investigation into myocarditis associated with immune checkpoint inhibitors.

In addition to her clinical and research work, Dr. Cheng is committed to education, mentorship, and advocacy. She previously served as Co-Chair of the Fellows-in-Training Committee for the California Chapter of the American College of Cardiology. Drawing on her background in health policy in Washington, D.C., she continues to advocate for equitable access to high-quality cardiovascular care.

#### CLINICAL FOCUS

- Cardiology
- Cardio-Oncology
- Cardiotoxicity

#### ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Cardiovascular Medicine

## BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, American Heart Association (2022 - present)
- Member, American College of Cardiology (2022 - present)
- Co-Chair, Fellows-in-Training Committee, California Chapter of American College of Cardiology (2024 - 2025)

## PROFESSIONAL EDUCATION

- Board Certification: Cardiology, American Board of Internal Medicine (2025)
- Fellowship: Stanford University Cardiovascular Medicine Fellowship Program (2025) CA
- Board Certification, National Board of Echocardiography , Echocardiography (2024)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2022)
- Residency: UCLA Internal Medicine Residency (2022) CA
- Medical Education: UC San Diego Office of the Registrar (2019) CA

## Research & Scholarship

---

### CURRENT RESEARCH AND SCHOLARLY INTERESTS

Cardio-oncology

Cardiotoxicity

Delivery of care

Health care systems

## Publications

---

### PUBLICATIONS

- **KALLISTATIN AMELIORATES DIABETIC CARDIOMYOPATHY BY REDUCING OXIDATIVE STRESS THROUGH THE MIR-34A-SIRT1-FOXO1 PATHWAY**  
Li, J., Zhang, H., Huang, X., Huang, Y.  
ELSEVIER SCIENCE INC.2026: A746
- **Seasons of risk: Investigating temporal trends in ICI-associated Myocarditis**  
Griffith, C., Park, E., Cheng, E., Mccroskey, S., Katsumoto, T., Zhu, H., Funchain, P.  
AMER ASSOC CANCER RESEARCH.2026
- **A large language model for complex cardiology care. *Nature medicine***  
O'Sullivan, J. W., Palepu, A., Saab, K., Weng, W. H., Amponsah, D. K., Cheng, E., Cheng, Y., Chu, E., Desai, Y., Elezaby, A., Fazal, M., Hussain, T., Jain, et al  
2026
- **REPLY: Pragmatic Troponin Surveillance for ICI Cardiotoxicity: Impactful Lessons From Real-World Practice. *JACC. CardioOncology***  
Cheng, E., Ivanovic, M., Witteles, R., Waliany, S., Zhu, H.  
2026; 8 (1): 96-97
- **Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving Immunotherapy. *JACC. CardioOncology***  
Cheng, E., Ivanovic, M., Chan, A., Xu, S., Franquiz, M., Lee, C., You, J., Fazal, M., Le Guen, Y., Batchelder, R., Reddy, S. A., Katsumoto, T., Ramchandran, et al  
2025
- **Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research. *Current treatment options in cardiovascular medicine***  
Chan, A., Torelli, S., Cheng, E., Batchelder, R., Waliany, S., Neal, J., Witteles, R., Nguyen, P., Cheng, P., Zhu, H.  
2023; 25 (12): 715-735

- **ACUTE CARDIOMYOPATHY AFTER INITIATION OF CABOZANTINIB, A MULTITYROSINE KINASE INHIBITOR**  
Cheng, E., Zhu, H.  
ELSEVIER SCIENCE INC.2023: 2670
- **Taken to heart-arrhythmic potential of heart-leaf sida, a banned ephedrine alkaloid: a case report.** *European heart journal. Case reports*  
Cheng, E., Hsiao, R., Feliciano, Z., Betancourt, J., Han, J. K.  
2022; 6 (1): ytac023
- **Bradyarrhythmias in Cardio-Oncology.** *South Asian journal of cancer*  
Fonseca, M., Cheng, E., Do, D., Haldar, S., Kuty, S., Yang, E. H., Ghosh, A. K., Guha, A.  
2021; 10 (3): 195-210
- **Long-term vs. recent-onset obesity: their contribution to cardiometabolic risk in adolescence.** *Pediatric research*  
Burrows, R., Correa-Burrows, P., Rogan, J., Cheng, E., Blanco, E., Gahagan, S.  
2019; 86 (6): 776-782
- **Light smoking is associated with metabolic syndrome risk factors in Chilean young adults.** *Acta diabetologica*  
Cheng, E., Burrows, R., Correa, P., Güichapani, C. G., Blanco, E., Gahagan, S.  
2019; 56 (4): 473-479
- **2018 Hope Babette Tang Humanism in Healthcare Essay Contest: Third Place Medical Student Essay.** *Academic medicine : journal of the Association of American Medical Colleges*  
Cheng, E.  
2018; 93 (10): 1482-1483